PKM and cancer: These included Eno1 [24], LDHB [25], NPM1 [26], PKM2 [27] and KPNA2 [28], which are commonly overexpressed in NSCLC, are associated with poor prognosis, and are therefore potentially relevant targets for cancer immunotherapy.